Japan, Sept. 16 -- ARX LLC,BIOXCEL THERAPEUTICS INC has got intellectual property rights for 'NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS.' Other related details are as follows:
Application Number: JP,2024-221682
Category (FI): A61K9/20,A61K31/4174,A61K9/70,A61K47/38,A61K47/10,A61P25/20,A61K9/12,A61K9/06
Stage: PROBLEM TO BE SOLVED: To provide methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without inducing significant sedation.SOLUTION: The disclosed methods are particularly suitable for treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar dis...